Adina Badea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Adina Badea has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Kara Lake Lynch
Department of Laboratory Medicine, University of California, San Francisco, CA, USA
3 shared publications - Ralph G. Nuzzo
Department of Chemistry University of Illinois at Urbana Champaign 600 South Mathews Avenue Urbana IL 61801 USA
3 shared publications Gabriel Popescu
Department of Electrical and Computer Engineering, 4055 Beckman Institute, MC 251, 405 N. Mathews, Urbana, IL, 61801, USA
2 shared publications- Jonathan V. Sweedler
University of Illinois Urbana−Champaign
2 shared publications - Mikhail Eugene Kandel
Department of Electrical and Computer Engineering, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States
2 shared publications Aaron W. Oraham
School of Chemical Sciences, University of Illinois-Urbana Champaign, Urbana, IL 61801, United States of America
1 shared publication
Latest Publications
- Open Access
Dose-additive and dose-dependent fetal testis toxicity of a nine-phthalate mixture in the rat
Phthalates (ortho-phthalic acid diesters) are used in a variety of manufacturing processes, particularly as non-covalent plasticizers in flexible polyvinyl chloride. Phthalates are male reproductive toxicants that disrupt the development of the fetal testis, resulting in malformed seminiferous cords, multinucleated germ cells (MNGs), and decreased testosterone production. We previously reported that MNGs were a sensitive, dose-dependent marker of dipentyl phthalate (DPEP) germ cell toxicity. To test whether germ cell effects of phthalates are dose-additive, we measured the induction of MNGs by a phthalate mixture. We treated timed pregnant Sprague Dawley rats with an equipotent mixture of nine phthalates, spanning a two-log dose range, from GD 17-21. We found that the phthalate mixture effects on morphogenesis of the testis, assessed through histological analysis of MNGs and seminiferous cord diameter were dose-additive. Consistent with prior results, we also found that the testosterone-reducing effect of the phthalate mixture was dose-additive and dose-dependent. Induction of MNGs had the lowest effective dose of any endpoint that we measured, with a benchmark dose (BMD 10 ) of 9.402 (6.093, 13.13) mg (∑ all phthalates)/kg/d, which is equivalent to a BMD 10 of 3.517 (2.275, 4.919) mg DPEP/kg/d, based on relative potency factors. Quantitative analysis of phthalate metabolites in dam serum showed that the metabolites were present in approximately the same relative concentrations as the parent compounds in the dosing mixture, but with lower levels of monocyclohexyl phthalate and monobenzyl phthalate. Proteomic and spatial transcriptomic analyses showed significant decreases in expression of Leydig cell genes and proteins involved in steroid hormone biosynthesis, as well as enrichment of proteins related to metabolism of lipids and amino acids. Proteomic BMD analysis produced a lowest BMDmedian of 2.156 (0.204, 27.830) mg (∑ all phthalates)/kg/d, which was within a 4.36-fold margin of the lowest apical endpoint BMD.
Open AccessDose-additive and dose-dependent fetal testis toxicity of a nine-phthalate mixture in the rat
Phthalates (ortho-phthalic acid diesters) are used in a variety of manufacturing processes, particularly as non-covalent plasticizers in flexible polyvinyl chloride. Phthalates are male reproductive toxicants that disrupt the development of the fetal testis, resulting in malformed seminiferous cords, multinucleated germ cells (MNGs), and decreased testosterone production. We previously reported that MNGs were a sensitive, dose-dependent marker of dipentyl phthalate (DPEP) germ cell toxicity. To test whether germ cell effects of phthalates are dose-additive, we measured the induction of MNGs by a phthalate mixture. We treated timed pregnant Sprague Dawley rats with an equipotent mixture of nine phthalates, spanning a two-log dose range, from GD 17-21. We found that the phthalate mixture effects on morphogenesis of the testis, assessed through histological analysis of MNGs and seminiferous cord diameter were dose-additive. Consistent with prior results, we also found that the testosterone-reducing effect of the phthalate mixture was dose-additive and dose-dependent. Induction of MNGs had the lowest effective dose of any endpoint that we measured, with a benchmark dose (BMD 10 ) of 9.402 (6.093, 13.13) mg (∑ all phthalates)/kg/d, which is equivalent to a BMD 10 of 3.517 (2.275, 4.919) mg DPEP/kg/d, based on relative potency factors. Quantitative analysis of phthalate metabolites in dam serum showed that the metabolites were present in approximately the same relative concentrations as the parent compounds in the dosing mixture, but with lower levels of monocyclohexyl phthalate and monobenzyl phthalate. Proteomic and spatial transcriptomic analyses showed significant decreases in expression of Leydig cell genes and proteins involved in steroid hormone biosynthesis, as well as enrichment of proteins related to metabolism of lipids and amino acids. Proteomic BMD analysis produced a lowest BMDmedian of 2.156 (0.204, 27.830) mg (∑ all phthalates)/kg/d, which was within a 4.36-fold margin of the lowest apical endpoint BMD.
- 29 March 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 71 (10) , 1022
Commentary on Supratherapeutic Carbamazepine Concentration Following a Recent SARS-CoV-2 Infection
- 29 March 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 71 (10) , 1022
Commentary on Supratherapeutic Carbamazepine Concentration Following a Recent SARS-CoV-2 Infection
- 12 March 2025
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 45 (2) , 177-186
Untargeted Mass Spectrometry Applications for Clinical Toxicology
- 12 March 2025
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 45 (2) , 177-186
Untargeted Mass Spectrometry Applications for Clinical Toxicology
- 1 August 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (8) , 1085-1086
Clinical Laboratories Confront a New Wave of Drug Overdose Deaths
The United States opioid epidemic has evolved over time to involve other classes of drugs and has become a polydrug overdose crisis. Over the course of 4 decades, the shifts in the number of overdose deaths have been characterized as “waves,” based on the drugs primarily responsible for each rise in overdose deaths. The first wave, starting in the late 1990s and early 2000s, was attributed to prescription opioids. The second wave, starting in 2010, was driven by increasing numbers of cases involving heroin, and the third wave, starting in 2013, was driven by fentanyl and its illicit analogs. A recent study ( 1) has characterized a fourth wave of overdose deaths and addresses the role of polysubstance use in fatal overdoses involving illicit opioids ( Fig. 1). This study examined finalized death records from 2010 through 2021 from the Centers for Disease Control and Prevention (CDC)’s Wide-Ranging Online Database for Epidemiologic Research to provide an in-depth, multivariable characterization of trends in overdose deaths in the United States. The study focused on the role of fentanyl and stimulants as factors shaping the dramatic shifts in overdose deaths. From 2010 to 2021, there was a significant rise in overdose fatalities, from 38 329 to 106 699. As the overall number of overdose deaths rose during the study period, so did the percentage involving both fentanyl and stimulants, from 0.6% in 2010 to 32.3% in 2021. In 2010, fentanyl occurred most frequently in copositivity with opioids, followed by alcohol, and benzodiazepines, across all states. The shift to stimulants as a major co-occurrence in fentanyl deaths followed different timelines in the 4 major geographic regions considered.
- 1 August 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (8) , 1085-1086
Clinical Laboratories Confront a New Wave of Drug Overdose Deaths
The United States opioid epidemic has evolved over time to involve other classes of drugs and has become a polydrug overdose crisis. Over the course of 4 decades, the shifts in the number of overdose deaths have been characterized as “waves,” based on the drugs primarily responsible for each rise in overdose deaths. The first wave, starting in the late 1990s and early 2000s, was attributed to prescription opioids. The second wave, starting in 2010, was driven by increasing numbers of cases involving heroin, and the third wave, starting in 2013, was driven by fentanyl and its illicit analogs. A recent study ( 1) has characterized a fourth wave of overdose deaths and addresses the role of polysubstance use in fatal overdoses involving illicit opioids ( Fig. 1). This study examined finalized death records from 2010 through 2021 from the Centers for Disease Control and Prevention (CDC)’s Wide-Ranging Online Database for Epidemiologic Research to provide an in-depth, multivariable characterization of trends in overdose deaths in the United States. The study focused on the role of fentanyl and stimulants as factors shaping the dramatic shifts in overdose deaths. From 2010 to 2021, there was a significant rise in overdose fatalities, from 38 329 to 106 699. As the overall number of overdose deaths rose during the study period, so did the percentage involving both fentanyl and stimulants, from 0.6% in 2010 to 32.3% in 2021. In 2010, fentanyl occurred most frequently in copositivity with opioids, followed by alcohol, and benzodiazepines, across all states. The shift to stimulants as a major co-occurrence in fentanyl deaths followed different timelines in the 4 major geographic regions considered.
- Open Access
- 15 June 2024
- Published by Springer Nature in Harm Reduction Journal
- Vol. 21 (1) , 1-6
An urgent need for community lot testing of lateral flow fentanyl test strips marketed for harm reduction in Northern America
Background: Fentanyl test strips (FTS) are lateral flow immunoassay strips designed for detection of ng/mL levels of fentanyl in urine. In 2021, the US Centers for Disease Control and the Substance Abuse and Mental Health Administration stated that federal funds could be used for procurement of FTS for harm reduction strategies approved by the government such as drug checking. The market for FTS has expanded rapidly in the US and Canada. However, there is no regulatory oversight by either government to ensure proper function of FTS that are being marketed for drug checking. Main body: Many brands of FTS have rapidly entered the harm reduction market, creating concerns about the reproducibility and accuracy of their performance from brand to brand and lot to lot. Some examples are provided in this Comment. Similar problems with product quality were observed in the mid 2000’s when lateral flow immunoassays for malaria were funded in many countries and again in 2020, when COVID-19 tests were in huge demand. The combination of high demand and low levels of regulation and enforcement led some manufacturers to join the goldrush without adequate field testing or quality assurance. We argue that the harm reduction community urgently needs to set a lot checking program in place. A set of simple protocols for conducting the tests and communicating the results have been developed, and are described in the following Perspectives paper in this issue. Conclusion: In the absence of governmental regulation and enforcement, the harm reduction community should implement a FTS lot checking program. Based on previous experience with the malaria diagnostic lot checking program, this inexpensive effort could identify products that are not suitable for harm reduction applications and provide valuable feedback to manufacturers. Dissemination of the results will help harm reduction organizations to ensure that FTS they use for drug checking are fit for the purpose.
- 15 June 2024
- Published by Springer Nature in Harm Reduction Journal
- Vol. 21 (1) , 1-6
Open AccessAn urgent need for community lot testing of lateral flow fentanyl test strips marketed for harm reduction in Northern America
Background: Fentanyl test strips (FTS) are lateral flow immunoassay strips designed for detection of ng/mL levels of fentanyl in urine. In 2021, the US Centers for Disease Control and the Substance Abuse and Mental Health Administration stated that federal funds could be used for procurement of FTS for harm reduction strategies approved by the government such as drug checking. The market for FTS has expanded rapidly in the US and Canada. However, there is no regulatory oversight by either government to ensure proper function of FTS that are being marketed for drug checking. Main body: Many brands of FTS have rapidly entered the harm reduction market, creating concerns about the reproducibility and accuracy of their performance from brand to brand and lot to lot. Some examples are provided in this Comment. Similar problems with product quality were observed in the mid 2000’s when lateral flow immunoassays for malaria were funded in many countries and again in 2020, when COVID-19 tests were in huge demand. The combination of high demand and low levels of regulation and enforcement led some manufacturers to join the goldrush without adequate field testing or quality assurance. We argue that the harm reduction community urgently needs to set a lot checking program in place. A set of simple protocols for conducting the tests and communicating the results have been developed, and are described in the following Perspectives paper in this issue. Conclusion: In the absence of governmental regulation and enforcement, the harm reduction community should implement a FTS lot checking program. Based on previous experience with the malaria diagnostic lot checking program, this inexpensive effort could identify products that are not suitable for harm reduction applications and provide valuable feedback to manufacturers. Dissemination of the results will help harm reduction organizations to ensure that FTS they use for drug checking are fit for the purpose.
- 7 July 2023
- Published by Elsevier in International Journal of Drug Policy
- Vol. 118
Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island
- 7 July 2023
- Published by Elsevier in International Journal of Drug Policy
- Vol. 118
Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island
- 29 August 2022
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 7 (6) , 1318-1328
An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results
Loperamide (Imodium®), a commonly used anti-diarrheal, is a mu opioid receptor agonist that, like all opioids, reduces gastrointestinal tract peristalsis. Loperamide is considered to have low abuse potential as it does not produce an analgesic or euphoric effect due to low bioavailability and first-pass metabolism. However, reports of individuals misusing loperamide through the use of super-therapeutic doses, alone or in combination with P-glycoprotein and/or CYP450 enzyme inhibitors, is increasing. We hypothesized that loperamide could potentially cross-react with laboratory immunoassay drug screens. Drug-free urine was spiked with loperamide or its principal metabolite, N-desmethyl loperamide (dLop), and assayed on multiple fentanyl and buprenorphine assays. Fentanyl immunoassay screen-positive results at one institution were examined by high-resolution mass spectrometry (MS) for the presence of loperamide and quantified by liquid chromatography– tandem MS when positive. Loperamide produced positive results on the Thermo DRI Fentanyl and Immunalysis Fentanyl assays at concentrations greater than 5.72 mg/L and 23.7 mg/L. dLop generated positive results for the Thermo DRI and Immunalysis fentanyl assays at concentrations exceeding 6.9 mg/L and 35.7 mg/L. dLop also produced positive buprenorphine results on the Thermo CEDIA buprenorphine assay at concentrations exceeding 12.2 mg/L. High-resolution MS analysis of 225 fentanyl immunoassay positives (Thermo DRI) yielded 5 specimens containing loperamide and/or dLop, 4 of which contained measurable quantities of fentanyl in addition to loperamide/dLop. Laboratories using these assays should be aware of the potential for false-positive screening results due to the presence of high concentrations of loperamide and its metabolite dLop.
- 29 August 2022
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 7 (6) , 1318-1328
An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results
Loperamide (Imodium®), a commonly used anti-diarrheal, is a mu opioid receptor agonist that, like all opioids, reduces gastrointestinal tract peristalsis. Loperamide is considered to have low abuse potential as it does not produce an analgesic or euphoric effect due to low bioavailability and first-pass metabolism. However, reports of individuals misusing loperamide through the use of super-therapeutic doses, alone or in combination with P-glycoprotein and/or CYP450 enzyme inhibitors, is increasing. We hypothesized that loperamide could potentially cross-react with laboratory immunoassay drug screens. Drug-free urine was spiked with loperamide or its principal metabolite, N-desmethyl loperamide (dLop), and assayed on multiple fentanyl and buprenorphine assays. Fentanyl immunoassay screen-positive results at one institution were examined by high-resolution mass spectrometry (MS) for the presence of loperamide and quantified by liquid chromatography– tandem MS when positive. Loperamide produced positive results on the Thermo DRI Fentanyl and Immunalysis Fentanyl assays at concentrations greater than 5.72 mg/L and 23.7 mg/L. dLop generated positive results for the Thermo DRI and Immunalysis fentanyl assays at concentrations exceeding 6.9 mg/L and 35.7 mg/L. dLop also produced positive buprenorphine results on the Thermo CEDIA buprenorphine assay at concentrations exceeding 12.2 mg/L. High-resolution MS analysis of 225 fentanyl immunoassay positives (Thermo DRI) yielded 5 specimens containing loperamide and/or dLop, 4 of which contained measurable quantities of fentanyl in addition to loperamide/dLop. Laboratories using these assays should be aware of the potential for false-positive screening results due to the presence of high concentrations of loperamide and its metabolite dLop.
- 7 January 2021
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 45 (3) , e8-e9
Lack of Cross-Reactivity of Tianeptine with Tricyclic Antidepressant Immunoassays
Adina Badea, Rohit Ghosh, Kara Lynch, Alan Wu; No Cross Reactivity of Tianeptine to Tricyclic Antidepressant Immunoassays, Journal of Analytical Toxicology, , b
- 7 January 2021
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 45 (3) , e8-e9
Lack of Cross-Reactivity of Tianeptine with Tricyclic Antidepressant Immunoassays
Adina Badea, Rohit Ghosh, Kara Lynch, Alan Wu; No Cross Reactivity of Tianeptine to Tricyclic Antidepressant Immunoassays, Journal of Analytical Toxicology, , b
- 23 February 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7) , 1759-1761
Real-time comprehensive toxicology testing in the clinical management of accidental pediatric capecitabine ingestion
Introduction: Capecitabine is an orally bioavailable prodrug of the chemotherapeutic agent, fluorouracil. Fluorouracil is converted to several active metabolites that induce a cytotoxic effect. Capecitabine toxicity can be life-threatening with a delayed presentation from ingestion. An oral antidote, uridine triacetate, exists but requires the administration of 20 total doses over a course of five days. Case report: In this report, we describe a case where timely coordination with a clinical toxicology laboratory was utilized to drive clinical decision making and management. Two children were brought to the emergency department shortly after suspected capecitabine ingestion. Management and outcome: Patients were admitted to the hospital and started on uridine triacetate. Real-time comprehensive toxicology testing of the children’s blood was used to rule out capecitabine toxicity and prevent several unnecessary days of hospitalization and doses of antidote. Patients were discharged safely. Discussion: Real-time comprehensive toxicology testing on a patient’s blood may be a valuable resource in ruling out or confirming toxic exposure in accidental pediatric ingestion of chemotherapeutic agents like capecitabine when performed in a timely manner.
- 23 February 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7) , 1759-1761
Real-time comprehensive toxicology testing in the clinical management of accidental pediatric capecitabine ingestion
Introduction: Capecitabine is an orally bioavailable prodrug of the chemotherapeutic agent, fluorouracil. Fluorouracil is converted to several active metabolites that induce a cytotoxic effect. Capecitabine toxicity can be life-threatening with a delayed presentation from ingestion. An oral antidote, uridine triacetate, exists but requires the administration of 20 total doses over a course of five days. Case report: In this report, we describe a case where timely coordination with a clinical toxicology laboratory was utilized to drive clinical decision making and management. Two children were brought to the emergency department shortly after suspected capecitabine ingestion. Management and outcome: Patients were admitted to the hospital and started on uridine triacetate. Real-time comprehensive toxicology testing of the children’s blood was used to rule out capecitabine toxicity and prevent several unnecessary days of hospitalization and doses of antidote. Patients were discharged safely. Discussion: Real-time comprehensive toxicology testing on a patient’s blood may be a valuable resource in ruling out or confirming toxic exposure in accidental pediatric ingestion of chemotherapeutic agents like capecitabine when performed in a timely manner.
- 22 November 2018
- Published by Wiley in Advanced Healthcare Materials
- Vol. 8 (1) , e1800788
3D‐Printed Hydrogel Composites for Predictive Temporal (4D) Cellular Organizations and Patterned Biogenic Mineralization
Materials chemistries for hydrogel scaffolds that are capable of programming temporal (4D) attributes of cellular decision‐making in supported 3D microcultures are described. The scaffolds are fabricated using direct‐ink writing (DIW)—a 3D‐printing technique using extrusion to pattern scaffolds at biologically relevant diameters (≤ 100 µm). Herein, DIW is exploited to variously incorporate a rheological nanoclay, Laponite XLG (LAP), into 2‐hydroxyethyl methacrylate (HEMA)‐based hydrogels—printing the LAP–HEMA (LH) composites as functional modifiers within otherwise unmodified 2D and 3D HEMA microstructures. The nanoclay‐modified domains, when tested as thin films, require no activating (e.g., protein) treatments to promote robust growth compliances that direct the spatial attachment of fibroblast (3T3) and preosteoblast (E1) cells, fostering for the latter a capacity to direct long‐term osteodifferentiation. Cell‐to‐gel interfacial morphologies and cellular motility are analyzed with spatial light interference microscopy (SLIM). Through combination of HEMA and LH gels, high‐resolution DIW of a nanocomposite ink (UniH) that translates organizationally dynamic attributes seen with 2D gels into dentition‐mimetic 3D scaffolds is demonstrated. These analyses confirm that the underlying materials chemistry and geometry of hydrogel nanocomposites are capable of directing cellular attachment and temporal development within 3D microcultures—a useful material system for the 4D patterning of hydrogel scaffolds.
- 22 November 2018
- Published by Wiley in Advanced Healthcare Materials
- Vol. 8 (1) , e1800788
3D‐Printed Hydrogel Composites for Predictive Temporal (4D) Cellular Organizations and Patterned Biogenic Mineralization
Materials chemistries for hydrogel scaffolds that are capable of programming temporal (4D) attributes of cellular decision‐making in supported 3D microcultures are described. The scaffolds are fabricated using direct‐ink writing (DIW)—a 3D‐printing technique using extrusion to pattern scaffolds at biologically relevant diameters (≤ 100 µm). Herein, DIW is exploited to variously incorporate a rheological nanoclay, Laponite XLG (LAP), into 2‐hydroxyethyl methacrylate (HEMA)‐based hydrogels—printing the LAP–HEMA (LH) composites as functional modifiers within otherwise unmodified 2D and 3D HEMA microstructures. The nanoclay‐modified domains, when tested as thin films, require no activating (e.g., protein) treatments to promote robust growth compliances that direct the spatial attachment of fibroblast (3T3) and preosteoblast (E1) cells, fostering for the latter a capacity to direct long‐term osteodifferentiation. Cell‐to‐gel interfacial morphologies and cellular motility are analyzed with spatial light interference microscopy (SLIM). Through combination of HEMA and LH gels, high‐resolution DIW of a nanocomposite ink (UniH) that translates organizationally dynamic attributes seen with 2D gels into dentition‐mimetic 3D scaffolds is demonstrated. These analyses confirm that the underlying materials chemistry and geometry of hydrogel nanocomposites are capable of directing cellular attachment and temporal development within 3D microcultures—a useful material system for the 4D patterning of hydrogel scaffolds.